



Advances in the Management of Diabetic Nephropathy

Guest Editors:

**Dr. Swayam Prakash
Srivastava**

Department of Pediatrics
(Nephrology), Vascular Biology &
Therapeutics, Yale University | YU,
New Haven, CT, USA

Dr. Surya Pandey

Department of Immunology,
University of Pittsburgh,
Pittsburgh, PA, USA

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editors

Diabetic nephropathy is a serious kidney-related complication of diabetes mellitus. About 25% of people with diabetes eventually develop kidney disease, and diabetes is also a leading cause of end-stage renal disease. The molecular and cellular basis of this renal disease is poorly understood, and this knowledge gap contributes to the suboptimal treatment options available for these patients. Improved understanding of the pathogenesis of diabetic nephropathy is urgently needed to catalyze the development of novel therapeutics. Current therapeutic regimens for these patients include ACE inhibitors, ARBs, and statins that can minimize the effects of the illness but not prevent it. However, side effects to these agents often exceed their overall efficacy. Thus, there is a clear medical need for new therapeutic strategies to improve kidney function in diabetic patients. In this Special Issue of *Pharmaceuticals*, we are inviting original as well as review articles to deepen our insight into the new pathophysiologic pathways, mechanisms, and advances in therapeutic approaches in the management of diabetic nephropathy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com